Anavex Life Sciences (AVXL) Stock Price

AVXLStock
$3.5667.37%52W
Market Cap$330.00M
P/E
PEG Ratio
Div yield
Beta1.16

AVXL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-34.27%
Price vs S&P 500 (4W)17.96%
VGM Score38.07

AVXL Earnings Surprise History

Q1 25-0.13est. -0.15
Q2 25-0.16est. -0.14
Q3 25-0.11est. -0.15
Q4 25-0.06est. -0.11
Q1 26-0.06est. -0.07

AVXL Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.14
4.14
4.14

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
AVXLAnavex Life Sciences
D$3.56
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Anavex Life Sciences

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing precision medicine treatments for central nervous system disorders with high unmet need. The company uses genomic biomarker analysis to advance programs targeting Alzheimer's disease, Parkinson's disease, schizophrenia, and rare neurological conditions including Rett syndrome. Its lead candidates, ANAVEX 2-73 and ANAVEX 3-71, are in clinical development, with additional compounds in earlier-stage programs.